Muromonab-CD3 (also known as Orthoclone OKT3) is a genetically engineered monoclonal antibody used to prevent organ rejection in transplant patients. It binds to a protein found on the surface of T-cells, a type of white blood cell, to prevent the immune system from attacking the new organ. Muromonab-CD3 is used in combination with other anti-rejection drugs and is usually given intravenously. It is used most often to treat kidney, heart and liver transplants, but may also be used in other types of transplants.
Muromonab-CD3, also known by the brand name Orthoclone OKT3, was an immunosuppressant medication previously used to prevent rejection in organ transplant recipients. It's important to note that it's no longer widely used due to the availability of safer and more effective medications. Here's a breakdown of its key features:
What it Does:
- Muromonab-CD3 belonged to a class of drugs called monoclonal antibodies.
- It specifically targeted the CD3 receptor, a protein found on the surface of T lymphocytes (T cells), which are essential components of the immune system.
- By binding to the CD3 receptor, Muromonab-CD3 suppressed the activity of T cells, thereby reducing the body's immune response.
- This was crucial in organ transplantation to prevent the immune system from attacking the transplanted organ.
Why it's not Widely Used Today:
- While effective in preventing rejection, Muromonab-CD3 had some significant drawbacks:
- Serious Side Effects: It could cause severe side effects like cytokine release syndrome, a potentially life-threatening inflammatory response.
- Short-lived Effect: Its immunosuppressive effect was short-lived, requiring multiple doses.
- Risk of Infections: Due to its strong immune suppression, it increased the risk of infections.
Replacement Medications:
- Safer and more targeted immunosuppressant medications have replaced Muromonab-CD3 for routine use in organ transplantation. These medications provide better control over the immune system with fewer side effects.
Current Use:
- Due to the availability of better alternatives, Muromonab-CD3 was withdrawn from the market in 2010.
- In very rare cases, it might be considered as a last resort for patients who experience severe rejection episodes unresponsive to other medications.